Health-care companies fell, but not by as much as the broad market, amid merger activity.
Health-care companies fell, but not by as much as the broad market, amid merger activity.
Eli Lilly agreed to buy biotech firm Merida Biosciences for up to $2.875 billion in cash, seeking to bulk up its immunology portfolio.
The iShares Biotech exchange-traded fund, a basket of biotechnology companies, rose in anticipation of more deals in the sub-sector.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to inflation…
Health-care companies fell as traders continued to rotate out of a sector beset by growth and regulatory concerns.
Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to…
Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs.
Health-care companies fell, but not by much, as traders continued rotating out of tech into lagging sectors.
Health-care companies rose amid deal intrigue.
